

***XRCC1* rs1799782 polymorphism and objective response rate in NSCLC patients treated with platinum-based chemotherapy.**

Peng-Cheng Wang[#], Xing Du[#], Yi Wang, Xiao-Li Zheng^{*}

Department of Pharmacy, the Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai 264000, PR China

[#]These authors contributed equally to this work.

Abstract

Background: Some previous studies suggested that *XRCC1* rs1799782 polymorphism was associated with the objective response rate (ORR) of platinum-based chemotherapy. However, the results were not coincident. Thus, we conducted this meta-analysis.

Methods: The databases of PubMed, Embase, Cochrane Library, and Web of Science were searched. This meta-analysis was performed using Stata version 12.0 (StataCorp LP, TX, USA).

Results: In this meta-analysis study, a total of 13 relevant articles with 2540 NSCLC patients were enrolled. Results of this meta-analysis study showed that the NSCLC patients with *XRCC1* rs1799782 Trp/Trp genotype were associated with worse ORR (OR=1.37; 95% CI, 1.01-1.79). In addition, *XRCC1* rs1799782 Arg/Trp genotype was associated with worse ORR (OR=1.41; 95% CI, 1.14-1.75). Furthermore, NSCLC patients with *XRCC1* rs1799782 Trp/Trp or Arg/Trp genotype also showed worse ORR (OR=1.39; 95% CI, 1.02-1.76).

Conclusions: In conclusion, this meta-analysis suggested that *XRCC1* rs1799782 polymorphism was significantly associated with ORR in NSCLC patients treated with platinum-based chemotherapy.

Keywords: *XRCC1*, NSCLC, Objective response rate, Chemotherapy.

Accepted on November 15, 2017

Introduction

Lung cancer is one of the leading causes of cancer-associated mortality. Non-small cell lung cancer (NSCLC) accounts for 80–85% of all lung cancer-associated mortalities [1]. Although a great number of therapeutic methods were extensively explored in clinical application, it has been verified that systemic chemotherapy can provide promising improvement in both survival rate and life quality for NSCLC patients [2]. X-ray repair cross complementing 1 (*XRCC1*) located at chromosome 19q13.2, is a key component of base excision repair (BER) and is required for genetic stability [3]. The *XRCC1* gene codes for a DNA-repair enzyme that is involved in base excision repair of oxidative DNA damage as well as single-strand break repair. Evidence has shown that polymorphisms in DNA repair genes could influence individual DNA repair capacity [4]. Lu et al. suggested that *XRCC1* Arg194Trp polymorphism was associated with increased risk for glioma, especially in Asians [5]. Yang et al. indicated that no association between *rs25487* or *rs1799782* gene polymorphism and risk of female reproductive cancer risk was found [6]. Jafari Nedooshan et al. found an increased risk of thyroid cancer with the *XRCC1* rs1799782 and *rs25487* polymorphisms [7]. Wang et al. suggested that Chinese Han people with rs1799782 TT/CT genotype of *XRCC1* gene may have increased risk of developing colorectal cancer [8]. Some

previous studies suggested that *XRCC1* rs1799782 polymorphism was associated with the objective response rate (ORR) of platinum-based chemotherapy [9-21]. However, the results were not coincident. Thus, we conducted this meta-analysis.

Materials and Methods

Publications Search

The databases of PubMed, Embase, Cochrane Library, and Web of Science were searched. Search terms included “X-ray repair cross complementing 1,” “*XRCC1*,” “non-small cell lung cancer,” “chemotherapy,” and “NSCLC.” Duplicated studies were excluded. Titles and abstracts were scanned thoroughly to exclude irrelevant articles. Finally, all of the full texts of the remaining articles were assessed comprehensively to identify the studies that contained the topic of interest.

Inclusion criteria and Data extraction

Inclusion criteria were as follows: (1) case-control or cohort studies; (2) NSCLC based on histopathological confirmation; (3) focused on the ORR of chemotherapy. The exclusion criteria were (1) non-English papers; (2) review articles, editorial comments, letters, expert opinion, conference

abstracts, or case reports. Data were extracted as follow: first author, year, country, ethnicity, and the sample sizes.

Statistical analysis

This meta-analysis was performed using Stata version 12.0 (StataCorp LP, TX, USA). For the analysis of the relationship between ORR and *XRCC1* rs1799782 polymorphism, ORs and 95% CIs were considered effective values. Heterogeneity among the studies was determined through Q and I² tests. All p-values were two sided, and statistical significance was set at p<0.05.

Results

Characteristics of the studies

As shown in Table 1, we identified 13 relevant articles through combined manual and computerized retrieval. Five studies were conducted in Caucasians and 8 studies were conducted in Asians. The sample sizes in each study ranged 82 to 378. Finally, a total of 2540 NSCLC patients were enrolled.

Table 1. The characteristics of the included cohort studies.

| Author/ Year | Country | Ethnicity subjects | Number subjects |
|----------------------|-------------|--------------------|-----------------|
| Gurubhagavatula/2004 | USA | Caucasian | 103 |
| de las Penas/2006 | Spain | Caucasian | 135 |
| Giachino/2007 | Italy | Caucasian | 249 |
| Sun/2009 | China | Asian | 82 |
| Hong/2009 | China | Asian | 164 |
| Qiu/2009 | China | Asian | 107 |
| Xu/2011 | China | Asian | 130 |
| Joerger/2012 | Netherlands | Caucasian | 131 |
| Zhao/2013 | China | Asian | 147 |
| Sullivan/2014 | Spain | Caucasian | 161 |
| Jin/2014 | China | Asian | 378 |
| Liu/2014 | China | Asian | 378 |
| Zhang/2014 | China | Asian | 375 |

Results of meta-analysis

Results of this meta-analysis study showed that the NSCLC patients with *XRCC1* rs1799782 Trp/Trp genotype were associated with worse ORR (OR=1.37; 95%CI, 1.01-1.79). In addition, *XRCC1* rs1799782 Arg/Trp genotype was associated with worse ORR (OR=1.41; 95%CI, 1.14-1.75). Furthermore, NSCLC patients with *XRCC1* rs1799782 Trp/Trp or Arg/Trp genotype also showed worse ORR (OR=1.39; 95%CI, 1.02-1.76).

Discussion

In this meta-analysis study, a total of 13 relevant articles with 2540 NSCLC patients were enrolled. Results of this meta-analysis study showed that the NSCLC patients with *XRCC1* rs1799782 Trp/Trp genotype were associated with worse ORR. In addition, *XRCC1* rs1799782 Arg/Trp genotype was associated with worse ORR. Furthermore, NSCLC patients with *XRCC1* rs1799782 Trp/Trp or Arg/Trp genotype also showed worse ORR. Putthanachote et al. suggested that *XRCC1* gene homozygosity, particularly Arg/Arg, on the risk for stomach cancer was elevated by a high intake of vegetable oils and salt [22]. Zhai et al. found that there are no correlations between *XRCC1* genotypes and ovarian carcinoma survival [23]. Zhang et al. indicated that *XRCC1* Arg399Gln GA variant might be risk alleles for cervical cancer susceptibility in the Chinese population [24]. Wang et al. suggested that *XRCC1* rs25487 A allele with bad survival for advanced NSCLC in Chinese population [25]. Sanjari Moghaddam et al. suggest that *XRCC1* gene polymorphisms modify breast cancer risk in different populations and different categories of menopausal status [26].

This meta-analysis has several limitations. First, the quality of all the included trials in this meta-analysis was low. Second, we did not perform subgroup analyses by ethnicity and gender. Third, the sample size was also relatively small in the included studies. In conclusion, this meta-analysis suggested that *XRCC1* rs1799782 polymorphism was significantly associated with ORR in NSCLC patients treated with platinum-based chemotherapy.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics 2015. *CA Cancer J Clin* 2015; 65: 5-29.
2. Jalal SI, Ademuyiwa FO, Hanna NH. The role of maintenance chemotherapy in advanced nonsmall cell lung cancer. *Curr Opin Oncol* 2009; 21: 110-115.
3. Taylor RM, Thistlethwaite A, Caldecott KW. Central role for the *XRCC1* BRCT I domain in mammalian DNA single-strand break repair. *Mol Cell Biol* 2002; 22: 2556-2563.
4. Cornetta T, Festa F, Testa A, Cozzi R. DNA damage repair and genetic polymorphisms: assessment of individual sensitivity and repair capacity. *Int J Radiat Oncol Biol Phys* 2006; 66: 537-545.
5. Lu JT, Deng AP, Song J, Zhang L, Luo J. Reappraisal of *XRCC1* Arg194Trp polymorphism and glioma risk: a cumulative meta-analysis. *Oncotarget* 2017; 8: 21599-21608.
6. Yang NN, Huang YF, Sun J, Chen Y, Tang ZM, Jiang JF. Meta-analysis of *XRCC1* polymorphism and risk of female reproductive system cancer. *Oncotarget* 2017; 8: 28455-28462.
7. Jafari Nedooshan J, Forat Yazdi M, Neamatzadeh H, Zare Shehneh M, Kargar S, Seddighi N. Genetic association of *XRCC1* Gene rs1799782, rs25487 and rs25489

- polymorphisms with risk of thyroid cancer: a systematic review and meta-analysis. *Asian Pac J Cancer Prev* 2017; 18: 263-270.
8. Wang L, Qian J, Ying C, Zhuang Y, Shang X, Xu F. X-ray cross-complementing groups 1 rs1799782 C>T polymorphisms and colorectal cancer susceptibility: A meta-analysis based on Chinese Han population. *J Cancer Res Ther* 2016; 12: C264-C267.
 9. Gurubhagavatula S, Liu G, Park S, Zhou W, Su L, Wain JC, Lynch TJ, Neuberg DS, Christiani DC. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. *J Clin Oncol* 2004; 22: 2594-2601.
 10. de Las Penas R, Sanchez-Ronco M, Alberola V, Taron M, Camps C, Garcia-Carbonero R. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. *Ann Oncol* 2006; 17: 668-675.
 11. Giachino DF, Ghio P, Regazzoni S, Mandrile G, Novello S, Selvaggi G, Gregori D, DeMarchi M, Scagliotti GV. Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer. *Clin Cancer Res* 2007; 13: 2876-2881.
 12. Sun X, Li F, Sun N, Shukui Q, Baoan C, Jifeng F. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients. *Lung Cancer* 2009; 65: 230-236.
 13. Hong CY, Xu Q, Yue Z, Zhang Y. Correlation of the sensitivity of NP chemotherapy in non-small lung cancer with DNA repair gene XRCC1 polymorphism. *Ai Zheng* 2009; 28: 1291-1297.
 14. Qiu LX, Qian XP, Liu BR, Hu WJ. Predictive value of XRCC1 polymorphisms in advanced non-small cell lung cancer patients receiving platinum-based chemotherapy. *Mod Oncol* 2009; 17: 263-265.
 15. Xu C, Wang X, Zhang Y, Li L. Effect of the XRCC1 and XRCC3 genetic polymorphisms on the efficacy of platinum-based chemotherapy in patients with advanced non-small cell lung cancer. *Zhongguo Fei Ai Za Zhi* 2011; 14: 912-917.
 16. Joerger M, Burgers SA, Baas P, Smit EF, Haitjema TJ, Bard MP, DoodemanVD, Smits PH, Vincent A, Huitema AD. Germline polymorphisms in patients with advanced non-small cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study. *Cancer* 2012; 118: 2466-2475.
 17. Zhao W, Hu L, Xu J, Shen H, Hu Z, Ma H, Shu Y, Shao Y, Yin Y. Polymorphisms in the base excision repair pathway modulate prognosis of platinum-based chemotherapy in advanced non-small cell lung cancer. *Cancer Chemother Pharmacol* 2013; 71: 1287-1295.
 18. Sullivan I, Salazar J, Majem M, Pallarés C, Del Río E, Páez D, Baiget M, Barnadas A. Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. *Cancer Lett* 2014; 353: 160-166.
 19. Jin ZY, Zhao XT, Zhang LN, Wang Y, Yue WT, Xu SF. Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer. *Genet Mol Res* 2014; 13: 7617-7625.
 20. Liu D, Wu J, Shi GY, Zhou HF, Yu Y. Role of XRCC1 and ERCC5 polymorphisms on clinical outcomes in advanced non-small cell lung cancer. *Genet Mol Res* 2014; 13: 3100-3107.
 21. Zhang L, Ma W, Li Y, Wu J, Shi GY. Pharmacogenetics of DNA repair gene polymorphisms in non-small-cell lung carcinoma patients on platinum-based chemotherapy. *Genet Mol Res* 2014; 13: 228-236.
 22. Putthanachote N, Promthet S, Hurst C, Suwanrungruang K, Chopjitt P, Wiangnon S, Chen SL, Yen AM, Chen TH. The XRCC1 DNA repair gene modifies the environmental risk of stomach cancer: a hospital-based matched case-control study. *BMC Cancer* 2017; 17: 680.
 23. Zhai XH, Huang J, Wu FX, Zhu DY, Wang AC. Impact of XRCC1, GSTP1, and GSTM1 polymorphisms on the survival of ovarian carcinoma patients treated with chemotherapy. *Oncol Res Treat* 2016; 39: 440-446.
 24. Zhang F, Li B, Wu HY, Shang LX. Association between X-ray repair cross-complementing group 1 Arg399Gln polymorphism and cervical cancer risk: a meta-analysis in the Chinese population. *Gynecol Obstet Invest* 2017; 82: 382-387.
 25. Wang S, Wang J, Bai Y, Wang Q, Liu L, Zhang K, Hong X, Deng Q, Zhang X, He M, Wu T, Xu P, Guo H. The genetic variations in DNA repair genes ERCC2 and XRCC1 were associated with the overall survival of advanced non-small-cell lung cancer patients. *Cancer Med* 2016; 5: 2332-2342.
 26. Sanjari Moghaddam A, Nazarzadeh M, Sanjari Moghaddam H, Bidel Z, Keramatnia A, Darvish H, Mosavi-Jarrahi A. XRCC1 gene polymorphisms and breast cancer risk: a systematic review and meta-analysis study. *Asian Pac J Cancer Prev* 2016; 17: 323-330.

***Correspondence to**

Xiao-Li Zheng

Department of Pharmacy

The Affiliated Yantai Yuhuangding Hospital of Qingdao University

PR China